Displaying drugs 6476 - 6500 of 8282 in total
Giroctocogene fitelparvovec
Giroctocogene fitelparvovec is under investigation in clinical trial NCT04370054 (Study to Evaluate the Efficacy and Safety of PF-07055480 in Moderately Severe to Severe Hemophilia a Adults).
Investigational
Matched Description: … fitelparvovec is under investigation in clinical trial NCT04370054 (Study to Evaluate the Efficacy and Safety of …
Revusiran
Revusiran is under investigation in clinical trial NCT02319005 (ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)).
Investigational
Matched Description: … Revusiran is under investigation in clinical trial NCT02319005 (ENDEAVOUR: Phase 3 Multicenter Study of …
siG12D LODER
siG12D LODER is under investigation in clinical trial NCT01676259 (A Phase 2 Study of Sig12d LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer).
Investigational
Matched Description: … siG12D LODER is under investigation in clinical trial NCT01676259 (A Phase 2 Study of Sig12d LODER in …
Talditercept alfa
Talditercept alfa is under investigation in clinical trial NCT03039686 (Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy).
Investigational
Matched Description: … investigation in clinical trial NCT03039686 (Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of …
ICG-136
ICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.
Investigational
Matched Description: … It was investigated for the treatment of acute myeloid leukemia. …
LuLym-T
LuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.
Investigational
Matched Description: … LuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. …
Mozafancogene autotemcel
RP-L102 is a lentiviral vector carrying the Fanconi Anemia-A (FANCA) gene currently being developed by Rocket Pharmaceuticals for the treatment of Fanconi anemia type A
Investigational
Matched Description: … Fanconi Anemia-A (FANCA) gene currently being developed by Rocket Pharmaceuticals for the treatment of …
ENTR-601-44
ENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.
Investigational
Matched Description: … Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy …
IMMU-114
IMMU-114 is antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific for alpha-chain linked to SN-38 via a CL2A linker.
Investigational
Matched Description: … IMMU-114 is antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific …
Belrestotug
Belrestotug is under investigation in clinical trial NCT05565378 (A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/metastatic Non-small-cell Lung Cancer).
Investigational
Matched Description: … Belrestotug is under investigation in clinical trial NCT05565378 (A Platform Study of Novel Immunotherapy …
Ciglitazone
Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.
Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market....
Experimental
Matched Description: … Ciglitazone is a potent and selective PPARγ ligand with an EC50 of 3.0 µM. ... Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones ... Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to …
MYR-101
MYR-101 (rAAV-Olig001-ASPA) is a recombinant adeno-associated virus (rAAV) vector-based gene therapy intended to treat Canavan disease. Canavan disease is a fatal childhood genetic disorder characterized by white matter degeneration in the brain. It is caused by a mutation in the aspartoacylase gene (ASPA), which leads to a deficiency of the...
Investigational
Matched Description: … ASPA is produced in oligodendrocytes, and participates in the metabolism of N-acetylaspartate (NAA). ... granted MYR-101 Fast Track, Rare Pediatric Disease (RPD), and Orphan Drug designations for the treatment of ... It is caused by a mutation in the aspartoacylase gene (_ASPA_), which leads to a deficiency of the aspartoacylase …
CZEN 002
CZEN-002 is a novel, non-azole anti-fungal synthetic octapeptide, derived from alpha-Melanocyte-Stimulating Hormone (a-MSH). CZEN-002 modulates inflammatory and immune responses. It has also been shown to kill Candida albicans (C. albicans), a single-celled fungal organism that causes a variety of infections, including vaginitis. This organism can invade tissues and produce fatal...
Investigational
Matched Description: … Studies attempting to understand the candidacidal activity of derivatives of alpha-MSH have focused on ... shown to kill Candida albicans (C. albicans), a single-celled fungal organism that causes a variety of ... The antimicrobial activity of CZEN-002 is unique in that it does not depend on direct damage to the microbial …
INO-4800
INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that the transfection of INO-4800 results in the expression of S protein by human cells.[A214475, A214478] Follow up studies in both...
Investigational
Matched Description: … Furthermore, the antibodies produced were capable of inhibiting the binding of SARS-CoV-2 to the ACE2 ... results in the expression of S protein by human cells. ... (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021. …
1-Testosterone
1-Testosterone is an anabolic steroid that differs from testosterone by having a 1,2-double bond instead of 4,5-double bond in its A ring.
Experimental
Illicit
Investigational
Matched Description: … Testosterone is an anabolic steroid that differs from testosterone by having a 1,2-double bond instead of …
Troxacitabine
Troxacitabine is a nucleoside analog with antineoplastic activity. There has been growing interest in its development for the treatment of patients with refractory lymphoproliferative conditions.
Investigational
Matched Description: … There has been growing interest in its development for the treatment of patients with refractory lymphoproliferative …
Anatibant
Anatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).
Investigational
Matched Description: … It is developed for the for the treatment of traumatic brain injury (TBI). …
AV608
AV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).
Investigational
Matched Description: … It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and …
PV903
PV903 is a self administered vaginally delivered recombinant protein for the treatment of recurrent miscarriage, resulting from an intolerant immune response to the developing foetus.
Investigational
Matched Description: … PV903 is a self administered vaginally delivered recombinant protein for the treatment of recurrent miscarriage …
OMS-103HP
OMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of the most common procedures performed today by orthopedic surgeons.
Investigational
Matched Description: … OMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of …
Strontium malonate
Strontium malonate is being developed as a novel orally available pharmaceutical for the treatment and prevention of osteoporosis. It is being developed by Osteologix Inc.
Investigational
Matched Description: … malonate is being developed as a novel orally available pharmaceutical for the treatment and prevention of …
Cetyl ethylhexanoate
Cetyl ethylhexanoate is an ester of cetyl alcohol and 2-ethylhexanoic acid. It is present in cosmetic products as a skin conditioning agent and emollient.
Experimental
Matched Description: … Cetyl ethylhexanoate is an ester of cetyl alcohol and 2-ethylhexanoic acid. …
MK-8776
Sch 900776 has been used in trials studying the treatment of Neoplasms, Hodgkin Disease, Adult Erythroleukemia, Lymphoma, Non-Hodgkin, and Myelogenous Leukemia, Acute, among others.
Investigational
Matched Description: … Sch 900776 has been used in trials studying the treatment of Neoplasms, Hodgkin Disease, Adult Erythroleukemia …
MK-0249
MK0249 has been used in trials studying the treatment of Hypopnea Syndrome, Alzheimer's Disease, Paranoid Schizophrenia, Sleep Apnea, Obstructive, and Excessive Daytime Sleepiness, among others.
Investigational
Matched Description: … MK0249 has been used in trials studying the treatment of Hypopnea Syndrome, Alzheimer's Disease, Paranoid …
PF-04691502
PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast Cancer (Phase 2), and Advanced Breast Cancer (Phase 1b).
Investigational
Matched Description: … PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast …
Displaying drugs 6476 - 6500 of 8282 in total